Procalcitonin is a well-known biomarker used to distinguish between bacterial and viral infections, assess a patient's risk category, and serve as a prognostic indicator. However, existing data are derived primarily from relatively young patients in intensive care units; there is a lack of information regarding the prognostic significance of procalcitonin in older patients hospitalized in internal medicine wards.
All patients hospitalized in internal medicine and geriatric wards with a diagnosis of acute infectious disease who underwent procalcitonin testing, starting in 2020.
Age under 18
Extensive burns
Major operation in the last 30 days
Major trauma in the last 30 days.
All patients hospitalized in internal medicine and geriatric wards with a diagnosis of acute infectious disease who underwent procalcitonin testing, starting in 2020.
Case-only
Retrospective
No Interventions
Other interventionNo intervention, retrospective observational study
Mortality
Evaluation of procalcitonin as a prognostic marker in patients hospitalized in the internal medicine and geriatric department by examining mortality during hospitalization, within 7 days and within 30 months.
Additional Outcomes - Length of stay
Comparison of procalcitonin and CRP as predictors of length of hospital stay
Additional data - morbidity
need for vasopressors or mechanical ventilation, need for intensive care, need for invasive intervention
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
